Healio55m
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Medical Dialogues7h
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
JD Supra18h
FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers
Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here's What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they ...